Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 235742, 9 pages
http://dx.doi.org/10.1155/2015/235742
Research Article

Systemic Inflammatory Markers Are Closely Associated with Atherogenic Lipoprotein Subfractions in Patients Undergoing Coronary Angiography

Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, BeiLiShi Road 167, Beijing 100037, China

Received 15 September 2015; Accepted 21 October 2015

Academic Editor: Consolato M. Sergi

Copyright © 2015 Yan Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Biasillo, M. Leo, R. Della Bona, and L. M. Biasucci, “Inflammatory biomarkers and coronary heart disease: from bench to bedside and back,” Internal and Emergency Medicine, vol. 5, no. 3, pp. 225–233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. G. K. Hansson, “Inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1626–1695, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. C. M. Ballantyne, R. C. Hoogeveen, H. Bang et al., “Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study,” Circulation, vol. 109, no. 7, pp. 837–842, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Eapen, P. Manocha, R. S. Patel et al., “Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes,” Journal of the American College of Cardiology, vol. 62, no. 4, pp. 329–337, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. Heart Protection Study Collaborative Group, “MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebocontrolled trial,” The Lancet, vol. 360, no. 9326, pp. 7–22, 2002. View at Publisher · View at Google Scholar
  6. C. Baigent, L. Blackwell, J. Emberson et al., “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials,” The Lancet, vol. 376, pp. 1670–1681, 2010. View at Google Scholar
  7. M. R. Diffenderfer and E. J. Schaefer, “The composition and metabolism of large and small LDL,” Current Opinion in Lipidology, vol. 25, no. 3, pp. 221–226, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Simic, M. Hermann, S. G. Shaw et al., “Torcetrapib impairs endothelial function in hypertension,” European Heart Journal, vol. 33, no. 13, pp. 1615–1624, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. G. G. Schwartz, A. G. Olsson, M. Abt et al., “Effects of dalcetrapib in patients with a recent acute coronary syndrome,” The New England Journal of Medicine, vol. 367, no. 22, pp. 2089–2099, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Tousoulis, C. Antoniades, and C. Stefanadis, “Assessing inflammatory status in cardiovascular disease,” Heart, vol. 93, no. 8, pp. 1001–1007, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Navab, N. Gharavi, and A. D. Watson, “Inflammation and metabolic disorders,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 11, no. 4, pp. 459–464, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Khovidhunkit, M.-S. Kim, R. A. Memon et al., “Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host,” Journal of Lipid Research, vol. 45, no. 7, pp. 1169–1196, 2004. View at Google Scholar · View at Scopus
  13. S. Li, Y.-L. Guo, R.-X. Xu et al., “Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease,” Atherosclerosis, vol. 234, no. 2, pp. 441–445, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Zhang, C.-G. Zhu, R.-X. Xu et al., “Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease,” Journal of Clinical Lipidology, vol. 8, no. 5, pp. 494–500, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. R.-X. Xu, S. Li, Y. Zhang et al., “Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease,” Lipids in Health and Disease, vol. 13, article 188, 2014. View at Publisher · View at Google Scholar
  16. M. Guardiola, N. Plana, D. Ibarretxe et al., “Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk,” Clinical Science, vol. 128, no. 12, pp. 877–882, 2015. View at Publisher · View at Google Scholar
  17. R. McPherson, “Remnant cholesterol: ‘Non-(HDL-C + LDL-C)’ as a coronary artery disease risk factor,” Journal of the American College of Cardiology, vol. 61, no. 4, pp. 437–439, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. D. M. Hoefner, S. D. Hodel, J. F. O'Brien et al., “Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System,” Clinical Chemistry, vol. 47, no. 2, pp. 266–274, 2001. View at Google Scholar · View at Scopus
  19. Y. Zhang, R.-X. Xu, S. Li et al., “Lipoprotein subfractions partly mediate the association between serum uric acid and coronary artery disease,” Clinica Chimica Acta, vol. 441, pp. 109–114, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. R.-X. Xu, Y.-L. Guo, X.-L. Li, S. Li, and J.-J. Li, “Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype,” Clinical and Experimental Pharmacology and Physiology, vol. 41, no. 7, pp. 475–481, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Ó Hartaigh, J. A. Bosch, D. Carroll et al., “Evidence of a synergistic association between heart rate, inflammation, and cardiovascular mortality in patients undergoing coronary angiography,” European Heart Journal, vol. 34, no. 12, pp. 932–941, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. R. P. Tracy, R. N. Lemaitre, B. M. Psaty et al., “Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 6, pp. 1121–1127, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Zhang, C.-G. Zhu, Y.-L. Guo et al., “Higher fibrinogen level is independently linked with the presence and severity of new-onset coronary atherosclerosis among han Chinese population,” PLoS ONE, vol. 9, no. 11, Article ID e113460, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. F. C. McGillicuddy, M. L. La Moya, C. C. Hinkle et al., “Inflammation impairs reverse cholesterol transport in vivo,” Circulation, vol. 119, no. 8, pp. 1135–1145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. K. E. Lewis, E. A. Kirk, T. O. McDonald et al., “Increase in serum amyloid A evoked by dietary cholesterol is associated with increased atherosclerosis in mice,” Circulation, vol. 110, no. 5, pp. 540–545, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. van Diepen, J. F. P. Berbée, L. M. Havekes, and P. C. N. Rensen, “Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis,” Atherosclerosis, vol. 228, no. 2, pp. 306–315, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. L. van Tits, R. Stienstra, P. van Lent, M. Netea, L. Joosten, and A. Stalenhoef, “Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Krüppel-like factor 2,” Atherosclerosis, vol. 214, no. 2, pp. 345–349, 2011. View at Publisher · View at Google Scholar
  28. A. Alipour, A. J. H. H. M. van Oostrom, A. Izraeljan et al., “Leukocyte activation by triglyceride-rich lipoproteins,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 4, pp. 792–797, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. E. M. DeGoma, M. D. Davis, R. L. Dunbar, E. R. Mohler, P. Greenland, and B. French, “Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis,” Atherosclerosis, vol. 229, no. 2, pp. 517–523, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. R. H. MacKey, P. Greenland, D. C. Goff Jr., D. Lloyd-Jones, C. T. Sibley, and S. Mora, “High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis),” Journal of the American College of Cardiology, vol. 60, no. 6, pp. 508–516, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. R. S. Rosenson, H. B. Brewer Jr., M. J. Chapman et al., “HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events,” Clinical Chemistry, vol. 57, no. 3, pp. 392–410, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. R. C. Hoogeveen, J. W. Gaubatz, W. Sun et al., “Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 5, pp. 1069–1077, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Nishikura, S. Koba, Y. Yokota et al., “Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease,” Journal of Atherosclerosis and Thrombosis, vol. 21, no. 8, pp. 755–767, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. T. B. Grammer, M. E. Kleber, W. März et al., “Low-density lipoprotein particle diameter and mortality: the Ludwigshafen Risk and Cardiovascular Health Study,” European Heart Journal, vol. 36, no. 1, pp. 31–38, 2015. View at Publisher · View at Google Scholar
  35. J. T. Salonen, R. Salonen, K. Seppänen, R. Rauramaa, and J. Tuomilehto, “HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction: a prospective population study in eastern finnish men,” Circulation, vol. 84, no. 1, pp. 129–139, 1991. View at Publisher · View at Google Scholar · View at Scopus
  36. R. X. Xu, S. Li, X. L. Li et al., “High-density lipoprotein subfractions in relation with the severity of coronary artery disease: a Gensini score assessment,” Journal of Clinical Lipidology, vol. 9, pp. 26–34, 2015. View at Google Scholar